Lipistad Filmuhúðuð tafla 20 mg Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

lipistad filmuhúðuð tafla 20 mg

stada arzneimittel ag - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 20 mg

Lipistad Filmuhúðuð tafla 40 mg Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

lipistad filmuhúðuð tafla 40 mg

stada arzneimittel ag - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 40 mg

Lipistad Filmuhúðuð tafla 80 mg Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

lipistad filmuhúðuð tafla 80 mg

stada arzneimittel ag - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 80 mg

Metoprolol Alvogen (Metoprolin) Tafla 100 mg Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

metoprolol alvogen (metoprolin) tafla 100 mg

alvogen ehf. - metoprololum tartrat - tafla - 100 mg

Metoprolol Alvogen (Metoprolin) Tafla 50 mg Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

metoprolol alvogen (metoprolin) tafla 50 mg

alvogen ehf. - metoprololum tartrat - tafla - 50 mg

Zofran Filmuhúðuð tafla 4 mg Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran filmuhúðuð tafla 4 mg

sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg

Zofran Filmuhúðuð tafla 8 mg Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran filmuhúðuð tafla 8 mg

sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 8 mg

Zofran Mixtúra, lausn 0,8 mg/ml Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

zofran mixtúra, lausn 0,8 mg/ml

sandoz a/s - ondansetronum hýdróklóríð - mixtúra, lausn - 0,8 mg/ml

Arexvy Unia Europejska - islandzki - EMA (European Medicines Agency)

arexvy

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - sýkingar af völdum sýklalyfja - bóluefni - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Abrysvo Unia Europejska - islandzki - EMA (European Medicines Agency)

abrysvo

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - sýkingar af völdum sýklalyfja - bóluefni - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. sjá kafla 4. 2 og 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.